01
Dec

Danish biotech Ascendis Pharma has put together a $60 million D round, cash that’ll help get its once-a-week treatment for growth hormone deficiency into late-stage testing.

…read more

Source: Ascendis banks $60M to get its orphan drug into Phase III

    

0 No comments